Independent pricing research and comparison guides across telehealth verticals. Filter by vertical or browse everything. All affiliate relationships disclosed.
Showing all 140 articles across 7 verticals
Androgenetic alopecia is driven by DHT acting on genetically sensitive follicles — how it works, how common it is, how it is diagnosed, and how it progresses.
Finasteride blocks the enzyme that converts testosterone into DHT — FDA approval, 1mg dosing, clinical trial results, and what to expect over time.
FDA-approved topical and off-label low-dose oral minoxidil — how they work, 2024 dosing consensus, trial results, and what happens if you stop.
FDA trial rates for sexual side effects, what happens after stopping, and how to read contested research on post-finasteride syndrome.
Combining finasteride and minoxidil outperforms either alone in trials — biology, meta-analyses, and how combo formulas get prescribed in practice.
Topical minoxidil is FDA-approved for female pattern hair loss; finasteride and spironolactone are off-label options with different evidence and safety tradeoffs.
Telogen effluvium causes sudden, diffuse hair shedding 2–3 months after stress, illness, or major life changes — here's how it differs from pattern hair loss and what recovery looks like.
Postpartum hair loss peaks around month 4 and usually resolves by your baby's first birthday — here's the hormonal cause, the full timeline, and when it's worth getting checked.
Losing 50–100 hairs a day is normal — here's how to self-check with the 60-second count and pull test, and the specific signs that mean it's time to see a dermatologist.
Minoxidil and finasteride both take months to show real results, with a normal "dread shed" phase early on for minoxidil users. Here's the realistic month-by-month timeline from clinical trials.
Dutasteride isn't FDA-approved for hair loss in the US and carries a much longer washout period than finasteride — but studies consistently show stronger hair-count results. Here's what the research actually shows.
Oral minoxidil started as a blood pressure medication with serious cardiovascular warnings. Here's what the safety data actually shows at low, hair-loss doses — and what screening should look like before you start.
Telehealth hair loss visits don't always require live video — but state law still requires a real evaluation. Here's what actually happens during intake, prescribing, and monitoring, and what to check before choosing a provider.
Neither drug cures androgenetic alopecia — both manage it while you're using them. Here's the realistic timeline for what happens after stopping, and what restarting does and doesn't restore.
Insurance rarely covers pattern hair loss treatment since it's typically classified as cosmetic — but FSA/HSA funds often can, even for OTC minoxidil. Here's when coverage actually applies and what treatment really costs.
Saw palmetto, biotin, and caffeine shampoos are marketed as natural alternatives to finasteride. Here's an honest look at what the actual clinical trials show for each — and where the marketing gets ahead of the evidence.
A transplant redistributes your existing follicles — it doesn't create new ones, and it doesn't protect the native hair around it. Here's how FUT and FUE compare, real costs, and why most surgeons recommend combining surgery with ongoing medication.
A complete pre-signup checklist covering medication and pharmacy questions, clinical oversight, cost transparency, and cancellation terms — everything worth confirming before you pay for telehealth hair loss treatment.
Compounded finasteride-minoxidil sprays aren't FDA-approved, even when the individual ingredients are well-studied. Here's what the FDA's own safety alert says, and what the evidence actually supports.
PRP injections aren't FDA-approved for hair loss and cost $500–1,500+ per session with no insurance coverage. Here's what the meta-analyses actually found on density, diameter, and how it compares to finasteride and minoxidil.
GLP-1 medications explained in plain language: what they are, how they work in your gut and brain, which drugs are FDA-approved for weight loss, and what clinical trials found.
Tirzepatide activates one more hormone receptor than semaglutide — and across every major trial, that difference shows up as more average weight loss.
Foundayo is a once-daily oral GLP-1 with no food or water restrictions — chemically different from semaglutide and tirzepatide, with convenience advantages over other oral options.
Wegovy and Ozempic both contain semaglutide — but they're approved for different uses, dosed differently, and covered differently by insurance.
The two FDA-approved weekly weight-loss injections compared on mechanism, trial results, cardiovascular approval, and available formulations.
Oral GLP-1 pills have closed much of the gap with weekly injections. Here's how the two approaches compare on results, convenience, and what the trial data actually shows.
Foundayo is a once-daily GLP-1 pill with no fasting rules — a different molecule type from semaglutide. Here's how it works, what the trials found, and how it compares.
Research on stopping GLP-1 medications like semaglutide and tirzepatide shows most people regain a significant share of lost weight. Here's what the data actually shows.
GLP-1 medications start affecting appetite within days, but meaningful weight loss builds over months. Here's the actual week-by-week timeline from clinical trial data.
A clear look at GLP-1 side effects — from common nausea to rare but serious risks — based on FDA labeling and adverse event data, plus what tends to help.
GLP-1 weight loss isn't all fat — research shows 20–40% can be lean muscle. Here's what the science says about why, and how nutrition and exercise can help protect it.
What it actually takes to get prescribed Wegovy, Zepbound, or another GLP-1 medication — eligibility criteria, the evaluation process, insurance steps, and realistic timelines.
A complete breakdown of who qualifies for GLP-1 weight-loss medications, who doesn't, and the specific contraindications and special-population considerations behind the FDA criteria.
The FDA doesn't require specific labs before starting a GLP-1 medication, but clinical guidelines recommend a standard set. Here's what's typically tested and why.
Compounded GLP-1 medications aren't FDA-approved and aren't reviewed for safety or quality before they're sold. Here's what that actually means and why the distinction matters.
The FDA-approved titration schedules for Wegovy, Zepbound, and Foundayo explained — plus why skipping steps or 'microdosing' claims deviate from tested, approved dosing.
If a provider prescribes compounded GLP-1 medication, here's exactly how to check whether the pharmacy is properly licensed and registered — 503A, 503B, and LegitScript explained.
GLP-1 insurance coverage varies enormously by plan type. Here's what commercial insurance, Medicare, and Medicaid actually cover in 2026, plus options if you're uninsured.
The Medicare GLP-1 Bridge offers eligible beneficiaries GLP-1 medications for $50/month starting July 2026. Here's exactly who qualifies, what's covered, and how it works.
A complete checklist of questions to ask any GLP-1 provider before you start — medication, clinical oversight, cost, and program quality — so nothing catches you off guard.
Practical, evidence-based nutrition guidance for GLP-1 treatment — what to eat to manage nausea, protect muscle, avoid nutrient gaps, and stay properly hydrated.
What testosterone replacement therapy actually does, who it is proven to help, and what the largest cardiovascular safety trial found.
What actually counts as low testosterone, the documented symptoms and causes, and when guidelines say it’s worth getting tested.
A clinically grounded symptom checklist and the next step guidelines recommend — testing, not self-diagnosis.
How enclomiphene works, how it differs from testosterone therapy, fertility-preservation research, and FDA status.
How injectable and topical testosterone differ in absorption, dosing pattern, and documented risks including transference.
Same drug class, same mechanism — but sildenafil and tadalafil differ in duration, dosing, food interactions, and side-effect profile.
How testosterone therapy affects sperm production, reversibility, and options to preserve or restore fertility.
Baseline and ongoing labs guidelines require for testosterone therapy — hematocrit, PSA, and testosterone monitoring explained.
Tadalafil comes in two FDA-approved dosing regimens — what head-to-head trials found on efficacy, side effects, and BPH overlap.
Which testosterone products have FDA approval, what conditions they cover, and what compounded TRT means.
How the three original PDE5 inhibitors compare on onset, duration, potency, and side effects — including vardenafil's QT warning.
How TRT and enclomiphene affect fertility, who is a candidate for each, and how to choose between them.
Why injection therapy works when oral ED meds fail, and the tradeoffs on speed, invasiveness, and side effects.
How brand-name, FDA-approved generic, and compounded sildenafil or tadalafil differ in regulatory review.
Licensure rules, controlled-substance requirements, and transparency standards that separate a legitimate provider from a red flag.
The diagnostic, prescribing, and fulfillment steps behind legitimate telehealth TRT — including DEA e-prescribing.
Testosterone is a controlled substance — the federal telehealth rules that apply today, and the Dec 31, 2026 expiration to watch.
What's in trimix and bimix, how each ingredient works, and what's FDA-approved versus compounded and unlicensed.
Why TRT pricing varies — delivery method, compounding vs brand-name, membership structure, and lab inclusion.
Why sildenafil, tadalafil, and injectable ED treatments land at different price points — formulation, dose, compounding, and billing.
What 'bioidentical' actually means, what the evidence says about who benefits most, and how HRT guidance has changed since the original WHI trial.
What actually distinguishes perimenopause from menopause, the real symptom range, and why guidelines recommend against routine hormone testing for most women.
Oral, transdermal, and vaginal estrogen aren't interchangeable — how they differ in risk, mechanism, and what each is meant to treat.
What's actually FDA-approved, what compounding covers, and what NASEM's 2020 review found.
What guidelines actually recommend for baseline assessment, when hormone testing genuinely helps, and what ongoing monitoring looks like.
Hormones aren't controlled substances, so HRT telehealth runs on a different regulatory track than TRT — what a legitimate evaluation looks like.
A practical walkthrough of intake, evaluation, prescribing, and follow-up — and where compounded and FDA-approved sourcing differ.
Menopause symptoms are common and treatable — here's the realistic symptom pattern worth discussing with a clinician, what else can mimic it, and when to actually book that visit.
Progesterone's main job in HRT is protecting the uterine lining — here's how that works, why FDA-approved micronized progesterone stands out, and what the real breast-cancer evidence actually shows.
Why HRT pricing varies so much between providers — membership structure, delivery method, compounded vs. FDA-approved sourcing, and insurance all shift the real cost.
PT-141 isn't 'female Viagra' — it's a centrally acting medication FDA-approved for a specific, narrow diagnosis. Here's the real mechanism, evidence, and regulatory scope.
Bremelanotide is FDA-approved — but only as one specific product, for one specific diagnosis. Here's exactly what that means, and why 'compounded PT-141' is a genuinely different thing.
Oxytocin's nickname as the 'bonding hormone' has outpaced the actual trial evidence for treating low libido. Here's an honest look at what the research really found.
One has FDA approval and phase 3 trial evidence behind it for a specific diagnosis. The other has a plausible mechanism and consistently underwhelming trial results.
HSDD is a real, distressing condition with a specific clinical definition — but low desire alone isn't automatically a diagnosis. Here's how it's actually assessed.
Vyleesi, a hypothetical generic, and compounded "PT-141" would all go through completely different FDA pathways.
Why sexual wellness pricing varies — treatment type, delivery route, and FDA-approved vs. compounded sourcing all shift the real cost.
Menopause hormone therapy and sexual wellness care answer different clinical questions — here's how they overlap, where they diverge, and why the right starting point is your actual symptom pattern.
The licensure rules, evaluation standards, and transparency signals that separate a legitimate HRT or sexual wellness provider from a red flag.
A practical checklist of questions to get clear answers to before payment — clinical purpose, clinician authorization, medication sourcing, and exit terms.
What a peptide actually is, the major categories you'll encounter, and the three questions worth asking about any specific peptide before you research further.
A July 2026 FDA advisory vote is reshaping this landscape in real time. Here's what's actually approved, what isn't, and what that vote does and doesn't mean today.
From intake to e-prescribing to your medication shipping out — here's what actually happens behind the scenes of a telehealth longevity visit.
For testosterone therapy specifically, a real, established monitoring protocol exists. Here's what a well-run longevity program should actually be checking, and when.
Most longevity treatments are compounded, not FDA-approved. Here's what that actually means legally, what oversight looks like, and what questions to ask before starting.
Licensing, prescribing rules, and consumer protections a legitimate longevity telehealth provider should already have in place — illustrated by a real 2025 FTC enforcement case.
Both are GHRH analogs that stimulate your own growth hormone — but their regulatory status and evidence base are genuinely different. Here's the real comparison.
NAD+ delivery routes aren't interchangeable. Here's what's actually been studied in humans for injection, IV, and nasal spray — and where the evidence runs out.
No official source tracks NAD+ pricing, and it changes often. Here's what actually drives the cost difference between providers — plus a live, current comparison.
NAD+ and sermorelin support two different biological systems, not two competing treatments. Here's how to think about which one fits what you're actually trying to support.
A mechanistically novel compound with consistently positive animal research behind it — here's what the science shows and where human research currently stands.
B12 injections are safe and genuinely effective for people with a real deficiency. Here's the honest, NIH-backed answer on what they do for everyone else.
The trial designed to test whether metformin extends healthy human lifespan has been ready since 2016 and still hasn't enrolled a single participant. Here's what the evidence actually shows.
Rapamycin has the strongest animal lifespan evidence of any longevity compound — but the human evidence is limited to one 48-week safety trial. Here's the honest gap between the two.
Methylene blue's mitochondrial mechanism and early cognition research, plus the FDA boxed-warning drug interaction that matters more than the marketing suggests.
LDN's fibromyalgia evidence has gotten weaker as the trials have gotten bigger — including a major 2026 study that found no benefit over placebo. Here's the full trajectory.
Tesamorelin's actual FDA approval is much narrower than how it's marketed for longevity — here's what's approved, what's been studied for cognition, and what's still genuinely uncertain.
What sermorelin actually does, its real FDA history, and an honest look at the body-composition and sleep evidence — including a finding that contradicts common marketing claims.
A plain-language guide to NAD+ therapy — what the research actually shows, how the delivery formats differ, and what to know before you pay for it.
Order-to-results pipeline, sample types, CLIA lab processing, and instant self-tests vs mail-in kits.
What CLIA regulates, waived vs higher-complexity testing, CAP accreditation, and accuracy limits.
Capillary vs venous concordance, hemolysis risks, and when an in-office draw is still preferable.
State variation in direct-access testing, partner-physician ordering, and abnormal-result follow-up.
Urgent vs routine next steps, why confirmation matters, and why home results are not prescriptions.
Self-test vs self-collection, which infections fit home pathways, and timing after exposure.
What IgG panels measure — and why AAAAI recommends against using them for allergy or intolerance diagnosis.
TSH, free T4/T3, and antibodies — what abnormal results mean and USPSTF screening limits.
LDL, HDL, triglycerides, and total cholesterol — risk context, fasting, and home vs office testing.
16S/metagenomics kits, scarce clinical usefulness, and DTC lab variability across companies.
2–3 month average glucose, CDC diagnostic thresholds, confirmation rules, and capillary concordance.
cfDNA methylation signals, non–FDA-approved LDT status, and why MCED must not replace proven screenings.
Diurnal cortisol rhythm, limits of single-point stress panels, and Endocrine Society Cushing guidance.
Screening and monitoring vs diagnosis — when kits help and when clinic care is required.
Sample quality tradeoffs across capillary, venous, and swab/urine collection for common kits.
CLIA lab disclosure, CAP accreditation, physician review, and red flags before you enroll.
Pre-purchase checklist: lab partner, review model, turnaround, redraws, and intended use.
FDA clearance of the test system vs CLIA certification of the lab — and what LDTs mean for consumers.
Cost drivers — single test vs panel vs membership, collection method, review fees — with live hub pricing.
Wellness baselines vs symptom-driven vs monitoring cadences — and why subscriptions are not guidelines.
Prescription skincare spans FDA-approved drugs like tretinoin and compounded multi-ingredient creams — how regulation differs and what telehealth programs actually sell.
Why tretinoin requires a prescription, how it differs from OTC retinol, and what compounded blends change about access.
When dermatologist review matters, who can legally prescribe topicals, and what major telehealth providers publicly disclose about credentials.
How legitimate telehealth skincare works, what compounded products mean, and red flags worth watching before you sign up.
Intake, prescriber review, compounding pharmacy fulfillment, and follow-up — a step-by-step look at online skincare prescribing.
How standard tretinoin percentages compare, why vehicle matters, and what compounded anti-aging formulas typically combine.
How hydroquinone lightens hyperpigmentation, duration limits, melasma use, and how compounded telehealth formulas apply it.
FDA-approved azelaic acid formulations, mechanism, and how compounded brightening blends use it alongside other actives.
Topical dapsone (Aczone) for inflammatory acne — mechanism, safety, and compounded telehealth variants vs. FDA-approved gel.
How rosacea topicals target redness vs. inflammatory lesions — FDA-approved options and compounded blend tradeoffs.
UV, hormones, and genetics drive melasma — why pigment returns without photoprotection and what prescription treatment must include.
Atrophic vs. hypertrophic scars — evidence for tretinoin and silicone gel, and when procedures beat topicals alone.
Prostaglandin lash growth mechanism, FDA-approved Latisse vs. compounded serums, and periorbital side effects.
Brand tubes, FDA-approved rosacea and acne drugs, and telehealth compounded blends — different regulatory paths explained.
Why telehealth favors all-in-one jars, irritation attribution challenges, and when simpler formulas win.
Licensure, pharmacy disclosure, compounded-vs-approved transparency, and follow-up access when comparing providers.
Pre-signup checklist: prescriber credentials, pharmacy sourcing, titration, pregnancy screening, cost, and cancellation.
Temporary acne flares after starting tretinoin — timeline, management, and how to distinguish purging from allergic reactions.
Photosensitivity with retinoids and pigment agents — morning SPF strategy and why melasma treatment fails without UV control.
Membership, compounded formula tiers, shipping, and how telehealth subscription pricing compares to generic tretinoin at retail.
Affiliate disclosure: RENVA may earn affiliate commissions from some provider links. Affiliate relationships do not influence provider scoring or editorial conclusions. Full disclosure →
Medical disclaimer: RENVA is not a healthcare provider. Content is informational and educational only. Always consult a licensed healthcare professional before making health decisions. Full disclaimer →